AlphAIAlphAI — Financial news for AI agents
yahoo.com$AUPH

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.

Original reporting
yahoo.com
Published Sep 16, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company — source image
Source · yahoo.com
Decision brief

The 30-second read

$AUPHNeutralMed
01

Why it matters

Earnings beat underscores leverage but raises questions on sustainable cash flow.

02

Market read

Earnings release provides fresh data for traders evaluating biotech exposure.

03

What to watch

Cash burn from share repurchase and upcoming Phase 4 study may strain liquidity.

Relevance 7/10Novelty 7/10Timing: post-market Aug 6 earnings release

Background

Aurinia's single‑product business model centers on LUPKYNIS for lupus nephritis.

Company-level read

Ticker impact

$AUPHNeutralMedium confidence
Context

Aurinia Pharmaceuticals reported Q2 earnings with revenue up 19% and net income up 74%, reiterating 2026 guidance.

Expected impact

Potential modest price increase of 3-5% on earnings beat, followed by stabilization.

Evidence & confidence

Earnings beat is material for a biotech, but scale is modest and cash usage remains high.

Market effects

Sector

Positive earnings may lift other lupus‑nephritis focused biotech peers.

Regional

Limited impact, primarily US biotech sector.

Global

Minimal global effect beyond niche biotech space.

Counterpoint

What could challenge this read

Higher R&D spend and tax expense could pressure margins, suggesting caution.

Key entities

  • Company
    Aurinia Pharmaceuticals Inc.

    Biotech firm focused on lupus nephritis treatment.

Read at source← All news

Also covered by

1 outlet

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K